WO2018003899A1 - 腎性貧血改善用組成物 - Google Patents
腎性貧血改善用組成物 Download PDFInfo
- Publication number
- WO2018003899A1 WO2018003899A1 PCT/JP2017/023851 JP2017023851W WO2018003899A1 WO 2018003899 A1 WO2018003899 A1 WO 2018003899A1 JP 2017023851 W JP2017023851 W JP 2017023851W WO 2018003899 A1 WO2018003899 A1 WO 2018003899A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- acid bacteria
- lactobacillus
- composition
- strain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 206010058116 Nephrogenic anaemia Diseases 0.000 title claims abstract description 50
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 220
- 241000894006 Bacteria Species 0.000 claims abstract description 113
- 239000004310 lactic acid Substances 0.000 claims abstract description 110
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 110
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000000047 product Substances 0.000 claims description 70
- 235000013305 food Nutrition 0.000 claims description 51
- 241000186660 Lactobacillus Species 0.000 claims description 24
- 229940039696 lactobacillus Drugs 0.000 claims description 24
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 22
- 235000015872 dietary supplement Nutrition 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 235000015140 cultured milk Nutrition 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 235000008476 powdered milk Nutrition 0.000 claims description 4
- 235000014347 soups Nutrition 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 244000294411 Mirabilis expansa Species 0.000 claims description 3
- 235000015429 Mirabilis expansa Nutrition 0.000 claims description 3
- 235000008452 baby food Nutrition 0.000 claims description 3
- 235000013536 miso Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 39
- 210000004027 cell Anatomy 0.000 description 46
- 235000013361 beverage Nutrition 0.000 description 23
- 102000001554 Hemoglobins Human genes 0.000 description 22
- 108010054147 Hemoglobins Proteins 0.000 description 22
- 238000011282 treatment Methods 0.000 description 17
- 239000000843 powder Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000006872 improvement Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000654 additive Substances 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 230000000813 microbial effect Effects 0.000 description 11
- -1 glycerin fatty acid ester Chemical class 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000003394 haemopoietic effect Effects 0.000 description 8
- 238000005534 hematocrit Methods 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000003951 Erythropoietin Human genes 0.000 description 7
- 108090000394 Erythropoietin Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 208000007502 anemia Diseases 0.000 description 7
- 230000035622 drinking Effects 0.000 description 7
- 229940105423 erythropoietin Drugs 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 4
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241000186713 Lactobacillus amylovorus Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000577554 Lactobacillus zeae Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000020152 coffee milk drink Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000021121 fermented vegetables Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006402 liver broth Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
Definitions
- the present invention relates to means and methods for improving renal anemia. Specifically, the present invention relates to a composition for improving renal anemia, which contains lactic acid bacteria and / or processed products thereof as active ingredients.
- Blood hemoglobin is known as an indicator of anemia, and the cause of anemia is known to be iron deficiency (inhibition of absorption) or renal (inhibition of hematopoietic hormone secretion from the kidney).
- iron deficiency inhibition of absorption
- renal inhibition of hematopoietic hormone secretion from the kidney.
- the promotion of absorbed iron by the administration of lactic acid bacteria and the improvement of renal function related to excretion have been reported.
- Patent Literature 1 discloses a composition for treating iron deficiency anemia comprising fermented milk fermented with lactic acid bacteria belonging to Lactobacillus acidophilus and an iron salt as active ingredients.
- Patent Document 2 discloses a composition in which probiotic bacteria such as Lactobacillus increase the excretory function in animal and human kidneys.
- Patent Document 3 describes that a living bacterium of Lactobacillus gasseri suppresses a decrease or deterioration in kidney function (renal metabolic function).
- Patent Document 4 describes that certain strains of Lactobacillus plantarum increase mammalian metal ion absorption.
- Non-Patent Document 1 describes that fermented milk using lactic acid bacteria belonging to Lactobacillus bulgaricus and Streptococcus thermophilus suppresses iron absorption and is not effective for iron deficiency anemia.
- An object of the present invention is to provide an effective means and method for improving renal anemia, particularly for a subject whose renal hematopoietic function is reduced.
- renal anemia can be improved in a subject by administering a lactic acid bacterium belonging to the genus Lactobacillus, particularly Lactobacillus gasseri or Lactobacillus amyloboraus. Specifically, it has been found that administration of lactic acid bacteria increases hemoglobin, erythrocytes and hematocrit or prevents their decrease.
- the present invention includes, but is not limited to: [1] A composition for improving renal anemia comprising a lactic acid bacterium belonging to the genus Lactobacillus and / or a processed product thereof as an active ingredient. [2] The composition according to [1], wherein the lactic acid bacterium is at least one selected from the group consisting of Lactobacillus gasseri and Lactobacillus amyloboraus. [3] Lactic acid bacteria are Lactobacillus gasseri CP2305 strain (Accession No. FERM BP-11331) or its mutant strain, Lactobacillus gaselli CP2305s strain (Accession No.
- the treated product of lactic acid bacteria is a treated product of disrupted cells.
- the food or drink includes a fermented milk beverage, yogurt, powdered milk, baby food, miso soup, retort food, and a tablet.
- [8] A method for improving renal anemia in a subject, comprising a step of administering lactic acid bacteria and / or a processed product thereof to the subject.
- [8-1] The method according to [8], wherein renal anemia in the subject is improved compared to a control not administered with the lactic acid bacterium and / or a processed product thereof.
- [9] A method for improving renal anemia in a subject, comprising administering lactic acid bacteria and / or a processed product thereof to the subject and improving renal anemia in the subject.
- a composition for improving renal anemia is provided.
- the composition of the present invention is effective for improving renal anemia, particularly in a subject whose renal hematopoietic function is reduced.
- the lactic acid bacteria which are active ingredients are safe and inexpensive, and can be easily ingested as food and drink or nutritional supplements.
- the present invention is based on the knowledge that renal anemia can be improved by administration of lactic acid bacteria. Specifically, as a result of administration of lactic acid bacteria (Lactobacillus gasseri CP2305 strain or Lactobacillus amylobolus CP1563 strain) for middle-aged and elderly people (40-90s), improvement of hemoglobin, etc. compared to placebo The effect is recognized, and this is based on the confirmation of the effect of lactic acid bacteria on improving renal anemia.
- lactic acid bacteria Lactobacillus gasseri CP2305 strain or Lactobacillus amylobolus CP1563 strain
- the present invention relates to a composition for improving renal anemia containing lactic acid bacteria and / or a processed product thereof as an active ingredient.
- the present invention also relates to a method for improving renal anemia in a subject, comprising the step of administering a lactic acid bacterium and / or a processed product thereof to the subject.
- the lactic acid bacteria used in the present invention are bacteria that produce lactic acid from saccharides by fermentation, and particularly include bacteria belonging to the genus Lactobacillus.
- a lactic acid bacterium strain known in the art can be used as long as the lactic acid bacterial cell or a processed product thereof exhibits an action for improving renal anemia as specifically described below. In consideration of administration / ingestion to animals, it is preferable that the strain has been confirmed to be safe in animals.
- More specific species of lactic acid bacteria include bacteria belonging to the genus Lactobacillus, Lactobacillus gasseri, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rhamnosus, Lactobacillus Reuteri, Lactobacillus acidophilus, Lactobacillus crispatas, Lactobacillus gallinarum, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus delbrukki Subspecies Bulgaricus, and Lactobacillus johnsonii and so on.
- the effect of improving renal anemia means the effect of improving renal anemia in a subject.
- Renal anemia is anemia caused by insufficient production of erythropoietin, a hematopoietic hormone that contributes to the production of red blood cells, due to a decrease in kidney function, resulting in insufficient red blood cell production.
- renal anemia is diagnosed when the hemoglobin level is 12.7 g / dL or less in adult men and 11.0 g / dL or less in adult women, and there is no anemia-causing disease other than decreased erythropoietin production.
- the Symptoms of renal anemia include palpitation, shortness of breath, dizziness, fatigue.
- Renal anemia is different from iron deficiency anemia caused by insufficient production of hemoglobin due to iron deficiency, but can also suffer from both renal anemia and iron deficiency anemia.
- “improvement” means to improve at least one of symptoms of renal anemia, increase hemoglobin and / or erythropoietin, normal value of hemoglobin and / or erythropoietin (in terms of hemoglobin, adult male 12.7 Approx.
- renal anemia can be determined by any method known in the art. For example, renal anemia can be determined by measuring blood hemoglobin, erythropoietin and / or hematocrit.
- lactic acid bacteria or treated products thereof have the desired renal anemia improvement action is determined by administering lactic acid bacteria belonging to the genus Lactobacillus or treated products thereof to experimental animals or test volunteers, etc.
- lactic acid bacteria belonging to the genus Lactobacillus or treated products thereof By confirming the improvement of renal anemia, it can be evaluated by confirming the improvement of renal anemia, for example, by measuring hemoglobin value, red blood cell count, hematocrit value, or by determining the symptoms of renal anemia.
- any lactic acid bacterium can be used as long as the microbial cell or the treated product is evaluated to have a renal anemia ameliorating action by the method as described above.
- Preferable lactic acid bacteria having such action include Lactobacillus gasseri CP2305 strain, Lactobacillus gasseri CP2305s strain and Lactobacillus amyloboras CP1563 strain.
- the Lactobacillus gasseri CP2305 strain was obtained by the applicant from the National Institute of Advanced Industrial Science and Technology (Ibaraki Prefecture, Japan), an independent administrative agency that is an international depositary authority based on the provisions of the Budapest Treaty for the deposit of patent microorganisms.
- Lactobacillus amyloborus CP1563 strain was registered by the applicant in May 2010 in the National Institute of Advanced Industrial Science and Technology, the Patent Organism Depositary, which is an international depositary authority based on the provisions of the Budapest Treaty for the deposit of patent microorganisms. Deposited internationally as deposit number FERM BP-11255 on the 25th. This stock has now been transferred to the International Depository Authority, the National Institute for Product Evaluation Technology Patent Biological Depositary Center (Kazusa Kamashitsu, Kisarazu City, Chiba, Japan, Room 2-5-8 120). Yes.
- the mutant strains of the specific strains described above can also be used as long as they have an action to improve renal anemia.
- the Lactobacillus gasseri CP2305s strain is a mutant obtained from the Lactobacillus gasseri CP2305 strain, and the CP2305 and CP2305s strains and the Lactobacillus amyroboras CP1563 strain have the effect of improving renal anemia as well.
- Such a mutant strain can also be used in the present invention.
- mutant strain means any strain obtained from the parent strain. Specifically, it is obtained by a method of artificially increasing the frequency of mutation from a parent strain by natural mutation or induced mutation by a chemical or physical mutagen, or by a specific mutagenesis technique (for example, gene recombination). Means a stock. A microbial individual produced by such a method is repeatedly selected and separated, and a useful microbial individual is bred to obtain a mutant having an action for improving renal anemia.
- the mutant strain derived from Lactobacillus gasseri CP2305 strain or CP2305s strain or Lactobacillus amyloboras CP1563 strain is different from other lactic acid strains by molecular weight distribution of amplified fragments of lactic acid bacteria genomic DNA by polymerase chain reaction (PCR) method. It can be easily identified. Briefly, for a target lactic acid bacterium, a DNA sample is prepared, and gene amplification is performed by PCR using primers having a characteristic sequence (for example, 16S rDNA base sequence). It is possible to determine whether or not it is a mutant strain derived from the CP2305 strain, the CP2305s strain, or the CP1563 strain. However, the method for confirming whether or not it is a mutant is not limited to this method, and it can be confirmed whether or not it is a mutant by a technique known in the art such as mycological properties. .
- PCR polymerase chain reaction
- Lactic acid bacteria can be prepared by culturing under appropriate conditions using a medium usually used for culturing lactic acid bacteria.
- a medium usually used for culturing lactic acid bacteria contains a carbon source, a nitrogen source, inorganic salts, and the like and can culture lactic acid bacteria efficiently, either a natural medium or a synthetic medium may be used. If so, a known medium suitable for the strain to be used can be appropriately selected. Lactose, glucose, sucrose, fructose, galactose, molasses etc. can be used as carbon source, and organic nitrogen containing casein hydrolyzate, whey protein hydrolyzate, soy protein hydrolyzate etc. as nitrogen source Things can be used.
- inorganic salts phosphates, sodium, potassium, magnesium and the like can be used.
- a medium suitable for culturing lactic acid bacteria include MRS liquid medium, GAM medium, BL medium, Briggs Liver Broth, animal milk, skim milk, and milky whey.
- a sterilized MRS medium can be used.
- lactic acid bacteria are cultured at 20 to 50 ° C., preferably 25 to 42 ° C., more preferably about 37 ° C. under anaerobic conditions.
- the temperature condition can be adjusted by a thermostatic bath, a mantle heater, a jacket, or the like.
- the anaerobic condition means a low oxygen environment in which lactic acid bacteria can grow.
- an anaerobic chamber, an anaerobic box, a sealed container or bag containing an oxygen scavenger, or the like is used.
- Anaerobic conditions can be achieved by sealing the culture vessel.
- the culture format is stationary culture, shake culture, tank culture, or the like.
- the culture time can be 3 to 96 hours.
- the pH of the medium at the start of the culture is preferably maintained at 4.0 to 8.0.
- lactic acid bacteria inoculate the lactic acid bacteria in a medium for lactic acid bacteria (for example, MRS liquid medium), preferably food grade lactic acid bacteria, Incubate overnight (approximately 18 hours) at approximately 37 ° C.
- a medium for lactic acid bacteria for example, MRS liquid medium
- the obtained lactic acid bacteria culture may be used as it is, or may be subjected to solid-liquid separation and / or sterilization by filtration and / or filtration if necessary.
- the lactic acid bacteria used in the present invention may be live cells or dead cells, may be wet cells, or may be dry cells. Preferably, dead lactic acid bacteria are used.
- a processed product of lactic acid bacteria obtained by processing microbial cells of lactic acid bacteria may be used, or a processed product of lactic acid bacteria may be further processed.
- An example of such processing is described below.
- It can be prepared as a suspension or dilution by suspending or diluting lactic acid bacteria and / or treated products in an appropriate solvent.
- solvent examples include water, physiological saline, phosphate buffered saline (PBS), and the like.
- a fermented product can be prepared by fermenting raw milk, skim milk powder or soy milk using lactic acid bacteria cells and / or processed products.
- lactic acid bacteria or other treated lactic acid bacteria are inoculated into raw milk, skim milk powder or soy milk, and fermented under lactic acid bacteria fermentation conditions known in the art (substantially the same as the lactic acid bacteria culture conditions described above).
- the obtained fermentation product may be used as it is, or may be subjected to other treatments such as filtration, sterilization, dilution and concentration.
- Lactic acid bacteria and / or treated products can be prepared as a sterilized product by sterilization.
- known sterilization processes such as filtration sterilization, radioactive sterilization, heating sterilization, and pressure sterilization can be performed.
- the lactic acid bacteria and / or the treated product are treated at a high temperature (for example, 80 to 150 ° C.) for a certain period of time, for example, about 10 minutes to 1 hour (for example, about 10 to 20 minutes). .
- a high temperature for example, 80 to 150 ° C.
- a certain period of time for example, about 10 minutes to 1 hour (for example, about 10 to 20 minutes).
- the “cell disrupted product” includes cells treated so that the cells are damaged by crushing, grinding, enzyme treatment, chemical treatment, dissolution, or the like.
- the “crushed material” includes, for example, a water-soluble fraction, an organic solvent-soluble fraction, an organic solvent and a poorly water-soluble fraction, an organic solvent and a water-insoluble fraction obtained after the microbial cell is damaged.
- the cells can be damaged by methods and equipment known in the art, for example, by physical disruption, enzyme dissolution treatment, chemical treatment, or autolysis treatment.
- Physical crushing may be carried out either wet (treated in the state of a cell suspension) or dry (treated in the state of a cell powder), using a homogenizer, ball mill, bead mill, dyno mill, planetary mill, etc.
- the cells can be damaged by stirring, by pressure using a jet mill, a French press, a cell crusher, or the like, or by filter filtration.
- an enzyme such as lysozyme can be used to destroy the cell structure of lactic acid bacteria.
- the chemical treatment can destroy the cell structure of lactic acid bacteria using a surfactant such as glycerin fatty acid ester and soybean phospholipid.
- the microbial cells can be dissolved by some lactic acid bacteria's own enzymes.
- the cell suspension or cell powder is stirred at 50 to 10,000 rpm, preferably 100 to 1,000 rpm.
- a specific method for preparing the crushed material is, for example, that a suspension of lactic acid bacteria is used in a known dynomill cell crusher (DYNO-MILL crusher etc.) and glass beads are used, and the peripheral speed is 10.0 to 20.0. 1 to 7 times (for example, 3 times) at a crushing tank temperature of 10 to 30 ° C (for example, about 15 ° C) at a processing flow rate of 0.1 to 10L / 10min (for example, about 1L / 10min) at m / s (for example, about 14.0m / s) Disrupt the cells by processing 5 times).
- a suspension of lactic acid bacteria is used in a known dynomill cell crusher (DYNO-MILL crusher etc.) and glass beads are used, and the peripheral speed is 10.0 to 20.0. 1 to 7 times (for example, 3 times) at a crushing tank temperature of 10 to 30 ° C (for example, about 15 ° C) at a processing flow rate of 0.1 to 10L / 10min
- a suspension of lactic acid bacteria can be discharged at a discharge pressure of 50 to 1000 MPa (eg 270 MPa) and a treatment flow rate of 50 to 1000 (eg 300 ml / min) in a known wet jet mill cell crusher (JN20 Nanojet Pal etc.). The cells are disrupted by treating 1 to 30 times (for example, 10 times).
- a known dry planetary mill cell crusher (GOT5 Galaxy 5 etc.)
- lactic acid bacteria powder is rotated in the presence of various balls (for example, zirconia 10 mm balls, zirconia 5 mm balls, alumina 1 mm balls) at 50 rpm.
- the cells can be disrupted by treatment at ⁇ 10,000 rpm (for example, 240 rpm, 190 rpm) for 30 minutes to 20 hours (for example, 5 hours).
- Lactic acid bacteria powder in a known dry-type jet mill cell crusher (jet O-mizer, etc.), supply speed 0.01 to 10000 g / min (eg 0.5 g / min), discharge pressure 1 to 1000 kg / cm 2 (eg 6 kg / cm)
- the cells may be crushed by treating 1 to 10 times (for example, once) at the pressure of 2 ).
- the microbial cell disrupted product is effective even when the cells are perforated, but it is desirable to prepare so that the average major axis of the microbial cell is 90% or less before the pulverization treatment.
- the average major axis of the bacterial cells may be 0%. Therefore, the average major axis of the microbial cells in the crushed cell product is 0 to 90%, preferably 0 to 80%, 0 to 70%, 0 to 50%, and more preferably 0 to 20% before pulverization. Crush lactic acid bacteria.
- the average major axis of the microbial cells in the crushed cell product varies depending on the type of lactic acid bacterium to be used, but for example, 0 to 2.5 ⁇ m, preferably 0 to 2 ⁇ m, more preferably 0 to 1.5 ⁇ m, 0 to 1 ⁇ m, and still more preferably. Is 0 to 0.5 ⁇ m.
- the average major axis can be calculated, for example, by measuring the major axis of 100 or more bacterial cells (including particles) and calculating the average value as the average major axis.
- an extract can be obtained by extracting lactic acid bacteria and / or a treated product using an appropriate aqueous solvent or organic solvent.
- the extraction method is not particularly limited as long as it is an extraction method using an aqueous solvent or an organic solvent as an extraction solvent, but the lactic acid bacterium or a processed product obtained by performing other treatments on the lactic acid bacterium is treated with an aqueous or organic solvent (for example, water, methanol). And a known method such as a method of immersing, stirring or refluxing in ethanol).
- the lactic acid bacteria cells and / or the treated product can be dried to form a powdery product (powder) or a granular product.
- a powdery product for example, spray drying, drum drying, vacuum drying, freeze-drying etc. are mentioned, These can be employ
- a component or fraction having an action to improve renal anemia may be purified from lactic acid bacteria and / or processed products using a known separation / purification method.
- separation / purification methods include methods utilizing solubility such as salt precipitation and organic solvent precipitation, methods utilizing differences in molecular weight such as dialysis, ultrafiltration and gel filtration, and ion exchange chromatography. Examples include methods that use the difference in charge, methods that use specific binding such as affinity chromatography, and methods that use hydrophobicity such as hydrophobic chromatography and reverse phase chromatography. Or two or more types can be used in combination.
- the lactic acid bacteria and / or processed product obtained above are used alone or in combination with other components as a composition of the present invention or in a food, drink, feed, nutritional supplement or pharmaceutical composition. Ingestion is expected to improve renal anemia.
- composition of the present invention contains the above-mentioned lactic acid bacteria and / or treated product as an active ingredient, but may contain one kind of lactic acid bacteria and / or treated product, or a plurality of different lactic acid bacteria.
- a body and / or a processed product, and a plurality of processed lactic acid bacteria processed differently may be included in combination.
- composition of the present invention in addition to the lactic acid bacteria and / or treated product of the active ingredient, the composition of the present invention, as long as it does not inhibit the targeted renal anemia ameliorating action, additives described later, other known drugs, You may add a nutritional supplement etc. individually or in combination.
- composition of the present invention is not particularly limited, and examples thereof include tablets, capsules, granules, powders, powders, syrups, dry syrups, liquids, suspensions, inhalants and other oral preparations, suppositories, and the like. It is good also as dosage forms, such as an enteral formulation, a drip, an injection. Of these, oral preparations are preferred. Liquid preparations such as liquids and suspensions may be dissolved or suspended in water or other appropriate medium immediately before taking. In the case of tablets and granules, the preparations may be prepared by well-known methods. The surface may be coated. Furthermore, the composition of the present invention may be a controlled release formulation such as sustained release formulation, delayed release formulation or immediate release formulation using techniques known in the art.
- Such a dosage form composition comprises the above-mentioned components, commonly used excipients, disintegrants, binders, wetting agents, stabilizers, buffers, lubricants, preservatives, surfactants, sweeteners.
- Additives such as flavoring agents, fragrances, acidulants, and coloring agents can be blended according to the dosage form, and can be produced according to conventional methods.
- a pharmaceutically acceptable carrier or additive can be blended.
- Such pharmaceutically acceptable carriers and additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, sodium alginate, water soluble dextran, water soluble dextrin , Sodium carboxymethyl starch, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerin, propylene glycol, polyethylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose, pharmaceutical additives
- an artificial cell structure such as a liposome can be used.
- the content of lactic acid bacteria and / or treated products as active ingredients varies depending on the dosage form, but the amount of lactic acid bacteria is usually Is in the range of 0.0001 to 99% by mass, preferably 0.001 to 80% by mass, more preferably 0.001 to 75% by mass, and the dosage per day can be controlled so that the desired intake of the active ingredient can be ingested. It is desirable to make it.
- the number of lactic acid bacteria or treated products contained in the composition of the present invention is about 10 7 / g to about 10 12 / g (in the case of treated products, the number of lactic acid bacteria before treatment).
- ESA erythropoiesis stimulating factor preparation
- various additives and other various substances used in the production of pharmaceuticals, foods and drinks, and feeds may coexist in the composition of the present invention.
- Such substances and additives include various fats and oils (for example, vegetable oils such as soybean oil, corn oil, safflower oil, olive oil, animal fats such as beef tallow and sardine oil), herbal medicines (eg royal jelly, carrots, etc.), Amino acids (eg, glutamine, cysteine, leucine, arginine, etc.), polyhydric alcohols (eg, ethylene glycol, polyethylene glycol, propylene glycol, glycerin, sugar alcohols such as sorbitol, erythritol, xylitol, maltitol, mannitol, etc.), natural polymers (For example, gum arabic, agar, water-soluble corn fiber, gelatin, xanthan gum, casein, gluten or gluten hydrolyzate, lecithin, starch, dextrin, etc
- the amount of these additives is appropriately determined according to the type of additive and the amount of intake to be desired, but the content of lactic acid bacteria and / or processed products as active ingredients varies depending on the dosage form.
- the amount of lactic acid bacteria before the treatment is usually preferably 0.0001 to 99% by mass, preferably 0.001 to 80% by mass, more preferably 0.001 to 75% by mass. .
- Subjects to be administered or ingested the composition of the present invention are vertebrates, specifically mammals such as humans, primates (monkeys, chimpanzees, etc.), livestock animals (bovines, horses, pigs, sheep, chickens, etc.). , Pet animals (dogs, cats, etc.), laboratory animals (mouse, rats, etc.), and reptiles and birds (chicks, etc.).
- mammals such as humans, primates (monkeys, chimpanzees, etc.), livestock animals (bovines, horses, pigs, sheep, chickens, etc.).
- Pet animals dogs (dogs, cats, etc.), laboratory animals (mouse, rats, etc.), and reptiles and birds (chicks, etc.).
- Particularly preferred are subjects for which improvement of renal anemia is desired, such as humans with impaired renal hematopoietic function, and humans whose hemoglobin levels are 13.5 g / dL or less for adult men and 11.5 g /
- the administration or intake of the composition of the present invention varies depending on the age and weight of the subject, the administration / intake route, the administration / intake frequency, the purpose of administration, etc., and can be achieved by those skilled in the art so that the intended effect of improving renal anemia can be achieved. It can be changed over a wide range at the discretion.
- the lactic acid bacteria and / or processed product contained in the composition is usually about 10 6 to about 10 12 per kg body weight as the amount of lactic acid bacteria, preferably It is desirable to administer about 10 7 to about 10 11 .
- the content ratio of the lactic acid bacteria and / or the processed product is not particularly limited, and may be appropriately adjusted according to the ease of production, the preferable daily dose, and the like.
- the intake can be further increased.
- the daily intake may be taken once, but may be taken in several divided doses.
- the frequency of administration or ingestion is not particularly limited, and can be appropriately selected according to the administration / intake route, the age and weight of the subject, and various conditions of the intended effect.
- the administration / intake route of the composition of the present invention is not particularly limited, and includes oral administration or ingestion, parenteral administration (eg, rectal, subcutaneous, intramuscular, intravenous administration) and the like.
- the composition of the present invention is particularly preferably administered or ingested orally.
- the composition of the present invention can effectively improve renal anemia, possibly by improving the decrease in renal function. Specifically, hemoglobin, erythrocytes or hematocrit in the subject is increased or prevented from being reduced as compared to a control not administered with the composition of the present invention (lactic acid bacteria and / or processed product thereof). Therefore, the composition of the present invention has an effect of improving renal anemia in a subject, particularly in a subject whose renal hematopoietic function is reduced.
- composition of the present invention may be used in combination with other medicines, treatment or prevention methods.
- Such other medicaments may form one preparation with the composition of the present invention, or may be administered in separate preparations at the same time or at intervals.
- composition of the present invention can be used as a pharmaceutical composition for improving renal anemia.
- the composition of the present invention is highly safe and easy to take for a long time. Therefore, the composition of this invention can be used also for food-drinks, a nutritional supplement, and feed.
- the composition of the present invention contains the lactic acid bacteria having an effect as described above and having food experience, and has high safety. Furthermore, even if added to various foods and drinks, it does not inhibit the flavor of the foods and drinks themselves, so it can be added to various foods and drinks and continuously ingested, and the expected effect of improving the intended renal anemia is expected.
- the food and drink of the present invention contains the above-described composition of the present invention.
- drinks are also included in the food and drink.
- the food and drink containing the composition of the present invention includes functional foods and drinks (nutritional supplements, foods for specified health use, nutritional functional foods, functional indication foods, etc.) that promote health by improving renal anemia, All foods and beverages that can be formulated with the composition of the present invention are included.
- the “functional food / beverage” of the present invention means a food / beverage having a certain functionality with respect to a living body, for example, a health functional food / beverage including a specific health food and a nutritional functional food, a functional indication food, a special food So-called health foods and drinks such as foods, nutritional supplements, health supplements and foods, supplements (for example, various dosage forms such as tablets, coated tablets, dragees, capsules and liquids) and beauty foods and drinks (for example, diet foods and drinks) Includes all.
- the functional food / beverage products of the present invention also include health food / beverage products to which health claims based on the food standards of Codex (FAO / WHO Joint Food Standards Committee) are applied.
- foods and drinks include liquid foods such as tube enteral nutrients, healthy foods and drinks in the form of preparations such as tablet confections, tablets, chewable tablets, tablets, powders, powders, capsules, granules and drinks, and Nutritional supplement food and drink; tea beverages such as green tea, oolong tea and black tea, soft drinks, jelly drinks, sports drinks, milk drinks, carbonated drinks, vegetable drinks, fruit juice drinks, fermented vegetable drinks, fermented fruit drinks, fermented milk drinks (yogurt, etc.) ), Lactic acid bacteria beverages, milk beverages (coffee milk, fruit milk, etc.), powdered beverages (milk powder, etc.), cocoa beverages, milk and beverages such as purified water; spreads such as butter, jam, sprinkles and margarine; mayonnaise, shortening, Custard cream, dressing, bread, cooked rice, noodles, pasta, miso soup, tofu, yogurt, baby food, soup or Sauces, confectionery products (for example, biscuits and cookies such, chocolate, candy, cake, ice cream,
- the food and drink according to the present invention include other food materials, various nutrients, various vitamins, minerals, dietary fiber, and various additives (for example, taste ingredients, sweet tastes) used in the production of the food and drink.
- various additives for example, taste ingredients, sweet tastes
- sour agents such as organic acids, stabilizers, flavors
- the blending amount of lactic acid bacteria which are active ingredients and / or processed products thereof can be appropriately determined by those skilled in the art in consideration of the form of the food / beverage products and the required taste or texture.
- the total amount of lactic acid bacteria and / or processed product in the composition to be added is 0.0001 to 99% by mass, preferably 0.001 to 80% by mass, more preferably 0.001 to 75% by mass as the amount of lactic acid bacteria.
- the blending amount is as follows. Since the composition of the present invention is highly safe, the blending amount in food and drink can be further increased. It is preferable that the daily intake can be controlled so that the desired intake can be eaten and consumed. Thus, by eating and drinking the food / beverage products of this invention in the form which can manage the desirable intake of the composition of this invention, the renal anemia improvement method using this food / beverage products is provided.
- the composition of the present invention may be contained in a food or drink by any appropriate method available to those skilled in the art. For example, after preparing the composition of this invention in the liquid form, the gel form, the solid form, the powder form, or the granular form, it can be mix
- the composition of the present invention may be applied, coated, penetrated or sprayed on food and drink.
- the composition of this invention may be disperse
- the composition of the present invention may be wrapped with an edible film or an edible coating agent.
- composition of this invention after adding a suitable excipient
- the food / beverage products containing the composition of the present invention may be further processed, and such processed products are also included in the scope of the present invention.
- the food and drink of the present invention have a useful effect and are highly safe and have no side effects.
- the composition of the present invention has a good flavor, and even when added to various foods and drinks, it does not inhibit the taste of the food or drink. Useful effects are expected.
- composition of the present invention can be blended not only in foods and drinks for humans, but also in animal feeds for livestock (cattle, pigs, chickens, etc.), racehorses, pets (dogs, cats, etc.). Since the feed is almost the same as the food and drink except that the subject is other than a human, the above description regarding the food and drink can be applied to the feed as well.
- Example 1 ⁇ Preparation of test beverage> Lactobacillus gasseri CP2305 strain and Lactobacillus helveticus were used to ferment skim milk powder and yeast extract at 32-37 ° C for 12-22 hours, and then the resulting fermented milk was liquid sugar, sweetener, acidulant , Formulated and sterilized with stabilizers and fragrances.
- the placebo was prepared and sterilized in the same manner as described above using milk fermented under the same conditions using Lactobacillus helveticus without using CP2305 strain. 200 ml of a sterilizing solution was filled in a paper container to obtain a test beverage and a placebo beverage.
- Example 2 ⁇ Human drinking test> Divided into 2 groups for 34 middle-aged and elderly people (40-90s), test beverages containing 10 or 10 Lactobacillus gasseri CP2305 strains, or placebo beverages not containing CP2305 strains 1 dose per day for 12 weeks.
- FIG. 1 shows the change in hemoglobin concentration with respect to drinking time (weeks).
- Lactobacillus amylovorus CP1563 strain is fermented at 37 ° C for 24 hours in a dietary medium using glucose, peptone, yeast extract, sodium acetate, dipotassium hydrogen phosphate, magnesium sulfate, glycerin fatty acid ester, then collected, washed and sterilized
- the cells were freeze-dried, and crushed cells were obtained at 0.5 kg / h under a pressure of 0.64 MPa using a FS-4 jet mill (Seishin company).
- skim milk powder, acidulant, sweetener, stabilizer, emulsifier, fragrance, and CP1563 crushed cells were mixed, sterilized and filled to prepare a test beverage.
- Example 4 ⁇ Human drinking test> A placebo-controlled, double-blind, comparative study was conducted on 200 subjects with a BMI of 25-30 kg / m 2 .
- the 500 ml beverage containing 200 mg of the above-described CP1563 disrupted microbial cells or the beverage containing no CP1563 was ingested every day for 12 weeks, and measurement was carried out at 0, 4, 8, and 12 weeks.
- FIG. 2 shows changes in concentrations of sodium ion, chloride ion and potassium ion with respect to drinking time (weeks), respectively.
- the organ responsible for the regulation of these electrolytes is the kidney, and it is considered that CP1563 strain, a lactic acid bacterium, controls hormone secretion that regulates the excretion and reabsorption of monovalent ions in the kidney.
- FIG. 3 shows changes in red blood cell count, hemoglobin concentration, and hematocrit with respect to drinking time (weeks), respectively.
- CP1563 strain which is a lactic acid bacterium
- lactic acid bacteria are involved in the control of hematopoietic hormones produced in the kidney.
Abstract
Description
特許文献2には、ラクトバチルスなどのプロバイオティックス細菌が動物及びヒトの腎臓における排泄機能を増大させる組成物が開示されている。
特許文献3には、ラクトバチルス・ガセリの生菌が腎臓機能(腎臓の代謝機能)の低下や悪化を抑制する旨が記載されている。
特許文献4には、ラクトバチルス・プランタラムの一定の株が哺乳動物の金属イオン吸収を増大させることが記載されている。
非特許文献1には、ラクトバチルス・ブルガリクス及びストレプトコッカス・サーモフィルスに属する乳酸菌を用いた発酵乳は鉄の吸収を抑制し、鉄欠乏性貧血には有効ではないことが記載されている。
[1] ラクトバチルス属に属する乳酸菌及び/又はその処理物を有効成分として含有する腎性貧血改善用組成物。
[2] 乳酸菌が、ラクトバチルス・ガセリ及びラクトバチルス・アミロボラスからなる群より選択される少なくとも1種である、[1]に記載の組成物。
[3] 乳酸菌が、ラクトバチルス・ガセリCP2305株(受託番号FERM BP-11331)若しくはその変異株、ラクトバチルス・ガセリCP2305s株(受託番号NITE BP-1405)若しくはその変異株、又はラクトバチルス・アミロボラスCP1563株(受託番号FERM BP-11255)若しくはその変異株である、[1]又は[2]に記載の組成物。
[4] 乳酸菌が死菌である、[1]~[3]のいずれかに記載の組成物。
[5] 乳酸菌処理物が菌体破砕処理物である、[1]~[4]のいずれかに記載の組成物。
[5-1] 投与対象が腎臓の造血機能が低下した対象である、[1]~[5]のいずれかに記載の組成物。
[5-2] 投与対象がヘモグロビンが低下した対象である、[1]~[5]のいずれかに記載の組成物。
[6] 組成物が、飲食品、飼料、栄養補助剤及び医薬からなる群より選択される、[1]~[5]のいずれかに記載の組成物。
[7] 飲食品が、発酵乳飲料、ヨーグルト、粉ミルク、ベビーフード、味噌汁、レトルト食品及びタブレットを含む、[6]に記載の組成物。
[8-1] 上記乳酸菌及び/又はその処理物を投与していない対照と比較して、上記対象における腎性貧血を改善する、[8]に記載の方法。
[9] 乳酸菌及び/又はその処理物を対象に投与し、対象において腎性貧血を改善するステップを含む、対象の腎性貧血を改善する方法。
酵素溶解処理は、例えばリゾチームなどの酵素を用いて、乳酸菌の細胞構造を破壊することができる。
薬品処理は、グリセリン脂肪酸エステル、ダイズリン脂質などの界面活性剤を使用して、乳酸菌の細胞構造を破壊することができる。
自己溶解処理は、一部の乳酸菌自身の酵素により菌体を溶解することができる。
(1)乳酸菌の準備
乳酸菌として、ラクトバチルス・ガセリCP2305株(受託番号FERM BP-11331)及びラクトバチルス・ガセリCP2305s株(受託番号NITE BP-1405)を準備した。
対象から血液を採取し、ラウリル硫酸ナトリウム-ヘモグロビン(SLS-Hb)法にてヘモグロビンを測定した。
対象からの血清を用いて、定法により電極法にて測定した。
対象から血液を採取し、電気抵抗検出法にて赤血球数、ヘマトクリット値を測定し、ラウリル硫酸ナトリウム-ヘモグロビン(SLS-Hb)法にてヘモグロビン濃度を測定した。
<試験飲料の調製>
ラクトバチルス・ガセリCP2305株及びラクトバチルス・ヘルベティカスを用いて、脱脂
粉乳及び酵母エキスを、32~37℃にて12~22時間発酵した後、得られた発酵乳に液糖、甘味料、酸味料、安定剤、香料で調合・殺菌した。
また、プラセボは、CP2305株を使用せずにラクトバチルス・ヘルベティカスを用いて同条件にて発酵した乳を用いて、上記と同様に調合・殺菌した。
殺菌液を紙容器に200ml充填し、試験飲料及びプラセボ飲料とした。
<ヒト飲用試験>
中高齢者(40~90歳代)34名を対象として2群に分け、ラクトバチルス・ガセリCP2305株を含有した試験飲料(菌体量として1010個)、又はCP2305株を含まないプラセボ飲料を、1日1本で12週間にわたり投与した。
<試験飲料の調製>
ラクトバチルス・アミロボラスCP1563株をグルコース、ペプトン、酵母エキス、酢酸ナトリウム、リン酸水素二カリウム、硫酸マグネシウム、グリセリン脂肪酸エステルを用いた食添培地で37℃24時間発酵後、集菌、洗浄、殺菌後、凍結乾燥し、FS-4ジェットミル(セイシン企業)を用いて0.64MPa圧力下で0.5kg/hにて破砕菌体を得た。次に、脱脂粉乳、酸味料、甘味料、安定剤、乳化剤、香料、CP1563破砕菌体を混合、殺菌、充填し、試験飲料を調製した。
<ヒト飲用試験>
BMIが25~30 kg/m2の被験者200名を対象に、プラセボ対照二重盲検比較試験を実施した。上記のCP1563破砕菌体200mgを含む500ml飲料、または含まない飲料を連日12週間摂取し、0、4、8、12週目で測定を実施した。
図3は、飲用時間(週)に対するそれぞれ赤血球数、ヘモグロビン濃度及びヘマトクリットの変化を示している。これらの赤血球の状態に関わる指標が乳酸菌であるCP1563株の摂取により維持されていることより、腎臓で産生される造血ホルモンの制御に乳酸菌(特にCP1563株)が関与していると考えられる。
受託番号NITE BP-1405(ラクトバチルス・ガセリCP2305s株、2012年8月14日付寄託)
受託番号FERM BP-11255(ラクトバチルス・アミロボラスCP1563株、2010年5月25日付寄託)
Claims (7)
- ラクトバチルス属に属する乳酸菌及び/又はその処理物を有効成分として含有する腎性貧血改善用組成物。
- 乳酸菌が、ラクトバチルス・ガセリ及びラクトバチルス・アミロボラスからなる群より選択される少なくとも1種である、請求項1に記載の組成物。
- 乳酸菌が、ラクトバチルス・ガセリCP2305株(受託番号FERM BP-11331)若しくはその変異株、ラクトバチルス・ガセリCP2305s株(受託番号NITE BP-1405)若しくはその変異株、又はラクトバチルス・アミロボラスCP1563株(受託番号FERM BP-11255)若しくはその変異株である、請求項1又は2に記載の組成物。
- 乳酸菌が死菌である、請求項1~3のいずれか1項に記載の組成物。
- 乳酸菌処理物が菌体破砕処理物である、請求項1~4のいずれか1項に記載の組成物。
- 組成物が、飲食品、栄養補助剤及び医薬からなる群より選択される、請求項1~5のいずれか1項に記載の組成物。
- 飲食品が、発酵乳飲料、ヨーグルト、粉ミルク、ベビーフード、味噌汁、レトルト食品及びタブレットを含む、請求項6に記載の組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17820253.7A EP3479837B1 (en) | 2016-06-30 | 2017-06-29 | Renal anemia ameliorating composition |
JP2018525243A JP6894097B2 (ja) | 2016-06-30 | 2017-06-29 | 腎性貧血改善用組成物 |
AU2017287988A AU2017287988A1 (en) | 2016-06-30 | 2017-06-29 | Renal anemia ameliorating composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-130811 | 2016-06-30 | ||
JP2016130811 | 2016-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018003899A1 true WO2018003899A1 (ja) | 2018-01-04 |
Family
ID=60785385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/023851 WO2018003899A1 (ja) | 2016-06-30 | 2017-06-29 | 腎性貧血改善用組成物 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3479837B1 (ja) |
JP (1) | JP6894097B2 (ja) |
AU (1) | AU2017287988A1 (ja) |
WO (1) | WO2018003899A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020036229A1 (ja) * | 2018-08-17 | 2020-02-20 | イチビキ株式会社 | 乳酸菌、血中鉄増加剤、及び貧血改善剤 |
KR102105316B1 (ko) * | 2018-11-16 | 2020-05-29 | 농업회사법인(주)백세 | 프로바이오틱스 유산균으로 발효된 차가버섯, 상황버섯 및 영지 버섯 혼합발효추출액을 이용한 기능성 음료의 제조방법 및 그 기능성 음료 |
JP2020132561A (ja) * | 2019-02-19 | 2020-08-31 | 雪印メグミルク株式会社 | エリスロポエチン産生促進用組成物 |
WO2021079869A1 (ja) * | 2019-10-21 | 2021-04-29 | ビオフェルミン製薬株式会社 | 尿毒素軽減剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018003900A1 (ja) * | 2016-06-30 | 2018-01-04 | アサヒグループホールディングス株式会社 | 栄養状態改善に使用するための組成物 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753391A (ja) | 1993-08-10 | 1995-02-28 | Snow Brand Milk Prod Co Ltd | 鉄欠乏性貧血治療用組成物 |
US20040258779A1 (en) * | 2003-06-06 | 2004-12-23 | Pinegrin Boris V. | Dietary and pharmaceutical compositions for treatment of anemia, thrombocytopenia, and leukopenia |
JP2007507526A (ja) | 2003-09-30 | 2007-03-29 | キボー バイオテック、インク | 腎臓機能を増大させるための組成物および方法 |
JP2008544753A (ja) | 2005-07-05 | 2008-12-11 | プロビ エービー | Fe、Zn、Caから選択される金属およびこれらのイオンの吸収を増大させるための乳酸桿菌の使用 |
WO2010038714A1 (ja) * | 2008-09-30 | 2010-04-08 | 明治乳業株式会社 | 高いシュウ酸分解能を有する乳酸菌 |
JP2014055195A (ja) | 2013-12-26 | 2014-03-27 | Snow Brand Milk Products Co Ltd | 加齢に伴う代謝異常症の予防・改善・治療剤 |
JP2014113137A (ja) * | 2012-11-16 | 2014-06-26 | Calpis Co Ltd | 新規の低温耐性ラクトバチルス・ガセリ株 |
CN104000183A (zh) * | 2013-12-09 | 2014-08-27 | 胡安然 | 一种调理贫血的膳食 |
JP2015108010A (ja) * | 2011-12-07 | 2015-06-11 | カルピス株式会社 | 乳酸菌又はその処理物を含む脂質代謝及び/又は糖代謝改善剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014077365A1 (ja) * | 2012-11-16 | 2014-05-22 | カルピス株式会社 | 特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤 |
-
2017
- 2017-06-29 AU AU2017287988A patent/AU2017287988A1/en active Pending
- 2017-06-29 WO PCT/JP2017/023851 patent/WO2018003899A1/ja unknown
- 2017-06-29 EP EP17820253.7A patent/EP3479837B1/en active Active
- 2017-06-29 JP JP2018525243A patent/JP6894097B2/ja active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753391A (ja) | 1993-08-10 | 1995-02-28 | Snow Brand Milk Prod Co Ltd | 鉄欠乏性貧血治療用組成物 |
US20040258779A1 (en) * | 2003-06-06 | 2004-12-23 | Pinegrin Boris V. | Dietary and pharmaceutical compositions for treatment of anemia, thrombocytopenia, and leukopenia |
JP2007507526A (ja) | 2003-09-30 | 2007-03-29 | キボー バイオテック、インク | 腎臓機能を増大させるための組成物および方法 |
JP2008544753A (ja) | 2005-07-05 | 2008-12-11 | プロビ エービー | Fe、Zn、Caから選択される金属およびこれらのイオンの吸収を増大させるための乳酸桿菌の使用 |
WO2010038714A1 (ja) * | 2008-09-30 | 2010-04-08 | 明治乳業株式会社 | 高いシュウ酸分解能を有する乳酸菌 |
JP2015108010A (ja) * | 2011-12-07 | 2015-06-11 | カルピス株式会社 | 乳酸菌又はその処理物を含む脂質代謝及び/又は糖代謝改善剤 |
JP2014113137A (ja) * | 2012-11-16 | 2014-06-26 | Calpis Co Ltd | 新規の低温耐性ラクトバチルス・ガセリ株 |
CN104000183A (zh) * | 2013-12-09 | 2014-08-27 | 胡安然 | 一种调理贫血的膳食 |
JP2014055195A (ja) | 2013-12-26 | 2014-03-27 | Snow Brand Milk Products Co Ltd | 加齢に伴う代謝異常症の予防・改善・治療剤 |
Non-Patent Citations (2)
Title |
---|
G. SCHAAFSMA ET AL., NETH. MILK DAIRY J., vol. 42, 1988, pages 135 - 146 |
SHARIATY Z. ET AL.: "The effects of probiotic supplement on hemoglobin in chronic renal failure patients under hemodialysis:A randomized clinical trial", JOURNAL OF RESEARCH IN MEDICAL SCIENCES, vol. 22, no. 3, June 2017 (2017-06-01), pages 1 - 7, XP055569399 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020036229A1 (ja) * | 2018-08-17 | 2020-02-20 | イチビキ株式会社 | 乳酸菌、血中鉄増加剤、及び貧血改善剤 |
JP6675521B1 (ja) * | 2018-08-17 | 2020-04-01 | イチビキ株式会社 | 乳酸菌、血中鉄増加剤、及び貧血改善剤 |
KR20210038631A (ko) * | 2018-08-17 | 2021-04-07 | 이치비키 가부시키가이샤 | 유산균, 혈중 철 증가제, 및 빈혈 개선제 |
CN112840017A (zh) * | 2018-08-17 | 2021-05-25 | 一引株式会社 | 乳酸菌、血中铁增加剂和贫血改善剂 |
EP3839042A4 (en) * | 2018-08-17 | 2022-06-01 | Ichibiki Co., Ltd. | LACTIC ACID BACTERIA, AGENT TO INCREASE BLOOD IRON LEVELS AND AGENT TO IMPROVE ANEMIA |
KR102656118B1 (ko) | 2018-08-17 | 2024-04-11 | 이치비키 가부시키가이샤 | 유산균, 혈중 철 증가제, 및 빈혈 개선제 |
KR102105316B1 (ko) * | 2018-11-16 | 2020-05-29 | 농업회사법인(주)백세 | 프로바이오틱스 유산균으로 발효된 차가버섯, 상황버섯 및 영지 버섯 혼합발효추출액을 이용한 기능성 음료의 제조방법 및 그 기능성 음료 |
JP2020132561A (ja) * | 2019-02-19 | 2020-08-31 | 雪印メグミルク株式会社 | エリスロポエチン産生促進用組成物 |
WO2021079869A1 (ja) * | 2019-10-21 | 2021-04-29 | ビオフェルミン製薬株式会社 | 尿毒素軽減剤 |
Also Published As
Publication number | Publication date |
---|---|
EP3479837C0 (en) | 2023-09-06 |
JPWO2018003899A1 (ja) | 2019-05-16 |
JP6894097B2 (ja) | 2021-06-23 |
EP3479837A4 (en) | 2020-03-25 |
EP3479837A1 (en) | 2019-05-08 |
EP3479837B1 (en) | 2023-09-06 |
AU2017287988A1 (en) | 2019-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011262840B2 (en) | Lipid metabolism-improving agent | |
JP5923238B2 (ja) | 迷走神経活性化剤 | |
JP6165185B2 (ja) | 乳酸菌又はその処理物を含む脂質代謝及び/又は糖代謝改善剤 | |
JP5686680B2 (ja) | 乳酸菌発酵によるカゼイン由来ペプチドの製造方法 | |
JP6894097B2 (ja) | 腎性貧血改善用組成物 | |
EP2478910B1 (en) | Anti-obesity agent, anti-obesity food or beverage, glucose tolerance-ameliorating agent, and food or beverage for amelioration of glucose tolerance | |
JP5888701B2 (ja) | 高タンパク質分解活性を有するラクトバチルス・ヘルベティカス菌 | |
JP6923883B2 (ja) | 栄養状態改善に使用するための組成物 | |
WO2018190407A1 (ja) | Toll様受容体2活性化用組成物 | |
JP2003252770A (ja) | 糖尿病合併症予防・改善・治療剤 | |
EP3479836B1 (en) | Cartilage regeneration facilitating composition | |
JP5950993B2 (ja) | 迷走神経活性化剤 | |
JP2021180619A (ja) | 整腸用茶発酵組成物及びその製造方法 | |
AU2015201076B2 (en) | Lipid metabolism-improving agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17820253 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018525243 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017820253 Country of ref document: EP Effective date: 20190130 |
|
ENP | Entry into the national phase |
Ref document number: 2017287988 Country of ref document: AU Date of ref document: 20170629 Kind code of ref document: A |